Business Trends– category –
-
Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: A Comparative Analysis of Advantages and Applications
Pharma Almanac USA Overview This comparative analysis explores the distinct strengths of lipid nanoparticles (LNPs) and viral vectors in gene delivery. While viral vectors like AAV and lentivirus excel in high-efficiency, durable gene ex... -
VIVEbiotech Scales In Vivo Gene Therapy Portfolio to 15 Programs, Securing Key FDA Clinical Trial Approvals
PharmaSource スペイン Overview Spanish CDMO VIVEbiotech has significantly expanded its in vivo lentiviral vector gene therapy portfolio to 15 programs, several of which have already secured regulatory clearance for clinical trials, inclu... -
Century Therapeutics Unveils CNTY-813 iPSC-Derived Islet Replacement Preclinical Data at ADA 2026: Demonstrates Durable Glucose Control, Immune Evasion, and Scalable Manufacturing, IND Filing Expected Q4 2026
BioSpace (via GlobeNewswire) USA Overview Century Therapeutics presented new preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the ADA 2026 Scientific Sessions. The data demonstrated durable glucose control, i... -
Preprint Reviews NKG2D CAR-NK Cell Progress in Cancer Immunotherapy: Low GVHD Risk, Scalable Manufacturing, and iPSC-Derived NK Cells as a Platform for Off-the-Shelf Therapies
Preprints.org International Overview A preprint on Preprints.org reviews recent progress in NKG2D CAR-NK cells for cancer immunotherapy, highlighting their favorable safety profile with rare instances of graft-versus-host disease (GVHD) ... -
Evotec Establishes GMP-Ready Automated 3D Stirred-Tank Bioprocess for iPSC-Derived Macrophages, Achieving Consistent Quality and High Yield
Evotec Germany Overview Evotec has announced the establishment of an automated, GMP-compliant 3D stirred-tank bioprocess for the scalable production of iPSC-derived macrophages. This innovative process suggests the capability to manufact... -
Cellares and TScan Therapeutics Partner to Automate Manufacturing of TCR-T Therapy Candidate TSC-101 for Hematologic Malignancies, Accelerating Commercialization
OTC Markets (BusinessWire) USA Overview Cellares and TScan Therapeutics announced an agreement to evaluate the automated manufacturing of TSC-101, a TCR-T cell therapy candidate for patients with hematologic malignancies. This collaborat... -
Made Scientific and Pluristyx Strengthen Alliance for iPSC Cell Therapy Manufacturing, Aiming to Reduce Rework and Accelerate Development Timelines
Made Scientific USA Overview Made Scientific and Pluristyx announced an enhanced strategic partnership to accelerate the development of iPSC-derived cell therapy candidates. This collaboration integrates Pluristyx's advanced iPSC platfor... -
Metacon Fuels 50MW Green Hydrogen Project with Key Payment and Capital Release
MarketScreener スウェーデン Overview Swedish hydrogen technology firm Metacon has announced a crucial €1.2 million payment for equipment, alongside the release of previously restricted bank funds, significantly bolstering its 50MW electr... -
H-Power Sells Two LC30 Fuel Cell Generators to TAMGO for Testing in Saudi Arabia, Targeting Extreme Conditions
London Stock Exchange UK Overview H-Power plc announced a deal to sell two LC30 fuel cell generators to TAMGO in Saudi Arabia. These generators will undergo performance and customer testing in Saudi Arabia, after which TAMGO will conduct... -
HELION Hydrogen Power and M REFORMER Forge Strategic Partnership to Integrate PEM Fuel Cells with Methanol Reforming
HELION Hydrogen Power France Overview HELION Hydrogen Power and M REFORMER have entered into an innovative strategic partnership focusing on the integration of Proton Exchange Membrane (PEM) fuel cell technology with methanol reformers. ...
